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Abstract
Background: In asthma and other allergic disorders, the activation of mast cells by IgE and antigen
induces the cells to release histamine and other mediators of inflammation, as well as to produce
certain cytokines and chemokines. To search for new mast cell products, we used complementary
DNA microarrays to analyze gene expression in human umbilical cord blood-derived mast cells
stimulated via the high-affinity IgE receptor (Fcε RI).
Results: One to two hours after Fcε RI-dependent stimulation, more than 2,400 genes (about half
of which are of unknown function) exhibited 2–200 fold changes in expression. The transcriptional
program included changes in the expression of IL-11 and at least 30 other cytokines and
chemokines. Human mast cells secreted 130–529 pg of IL-11/106 cells by 6 h after stimulation with
anti-IgE.
Conclusion: Our initial analysis of the transcriptional program induced in in vitro-derived human
mast cells stimulated via the Fcε RI has identified many products that heretofore have not been
associated with this cell type, but which may significantly influence mast cell function in IgE-
associated host responses. We also have demonstrated that mast cells stimulated via the Fcε RI can
secrete IL-11. Based on the previously reported biological effects of IL-11, our results suggest that
production of IL-11 may represent one link between IgE-dependent mast cell activation in subjects
with allergic asthma and the development of a spectrum of structural changes in the airways of
these individuals; such changes, collectively termed "airway remodeling," can constitute an
important long term consequence of asthma.
Background
In asthma and other allergic disorders, the activation of
mast cells by IgE and antigen induces the cells to release
histamine and other mediators of inflammation [1,2], as
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well as to produce certain cytokines and chemokines [1–
4]. To search for new mast cell products, we used cDNA
microarrays to analyze the transcriptional program in
highly pure populations of human mast cells that had
been stimulated via the Fcε RI. While others have analyzed
transcriptional profiles in certain rodent or human mast
cell populations using microarray-based or alternative ap-
proaches [6–10], the transcriptional profile of human
mast cells stimulated via the Fcε RI has not yet been report-
ed.
One of the many transcripts we found to be substantially
induced in human mast cells stimulated via Fcε RI was that
for IL-11, a pleiotropic cytokine that has been implicated
in airway inflammation and remodeling [11–13]; mast
cells stimulated via the Fcε RI also secreted IL-11 protein.
These results indicate that analysis of the transcriptional
profile of human mast cells stimulated by aggregation of
Fcε RI may be useful in suggesting new potential therapeu-
tic targets in asthma and other IgE-associated allergic dis-
orders.
Results and discussion
Fcε RI-dependent activation of human mast cells results in 
substantially altered expression of over 2,400 genes
The two mast cell preparations shown in Fig. 1 released
56.6 ± 4.1 or 63.0 ± 1.8% of their total histamine content
by 1 h after anti-IgE stimulation (vs. 1.7 ± 0.1 or 3.4 ± 0.2
%, respectively, in controls not stimulated with anti-IgE, p
< 0.001 for either comparison), which is a strong secretory
response in this mast cell type [15]. The transcriptional re-
sponses in these two populations were quite similar, with
2,478 genes exhibiting a 2–200 fold change in expression
over baseline levels; about half of these 2,478 genes repre-
sent unnamed expressed sequence tags (ESTs) of genes of
unknown functions (Fig. 1A). The reliability of the ob-
served changes was tested by including replicate array ele-
ments representing the same gene for ~25% of the genes;
these generally gave excellent agreement. A searchable ver-
sion of Fig. 1A, raw array images and the actual quantita-
tive array data from these experiments are available on the
Stanford Microarray Database web site  [http://genome-
www.stanford.edu/mast/] .
We observed changes in expression for 18 cytokines and
one cytokine-related molecule (tumor necrosis factor-α
converting enzyme, or TACE) (Fig. 1B), as well as 13
chemokines (Fig. 1C), including two CXC chemokines
(IL-8 and Gro2), one C chemokine (lymphotactin), and
ten CC chemokines (16) (Fig. 1C); several of these re-
sponses have not previously been reported (see symbols
in Fig. 1B & 1C). Several genes involved in potential inter-
actions with T cells, B cells or dendritic cells were upregu-
lated, and one, the CD40 ligand, was substantially
downregulated (Fig. 1D). Anti-IgE activated human mast
cells also altered the expression of several adhesion mole-
cules (Fig. 1E).
The results presented in Fig. 1 from two mast cell popula-
tions, and those from another experiment (donor 3) in
which the mast cells were derived using a different cell cul-
ture protocol and were challenged with anti-IgE at 1.0 µg/
ml (see website for details), indicate that umbilical cord
blood-derived mast cells from different donors may ex-
hibit similar transcriptional profiles after IgE-dependent
stimulation. However, additional studies will be required
to characterize the extent of the similarities and differenc-
es of the transcriptional profiles in mast cell populations
derived from different donors, different sources of pro-
genitor cells or different conditions of culture.
Secretion of IL-11 by mast cells activated via the Fcε RI
To assess whether increased expression of IL-11 mRNA
(Fig. 1B; 3.0 fold and 4.7 fold increases in mRNA expres-
sion vs. baseline levels at 2 h after stimulation in donors
1 & 2, respectively) was associated with synthesis of the
corresponding protein, we measured IL-11 secreted into
the medium at 6 h after the Fcε RI-dependent stimulation
of mast cells (> 99% purity) derived from 3 different do-
nors. The populations released 68.3 ± 4.7, 63.9 ± 2.6 or
34.8 ± 1.2 % of the total histamine within 1 h of stimula-
tion (vs. 2.1 ± 0.2, 1.7 ± 0.2 or 2.2 ± 0.1% for cells not
stimulated with anti-IgE, p < 0.001 for each comparison)
and secreted 130–529 pg of IL-11/106 cells at 6 h after
stimulation with anti-IgE, whereas little or no IL-11 was
released by the control cells (Fig. 2A). In a separate set of
experiments, we found that the maximal levels of IL-11
production were detected 12 h after stimulation with anti-
IgE (Fig. 2B).
It has been reported that the expression of IL-11 can be
greatly increased in both airway epithelial cells and resi-
dent inflammatory cells in subjects with severe asthma
[11]. Moreover, IL-11 mRNA was co-localized with major
basic protein (MBP) in inflammatory cells in the subepi-
thelial layer of the airway [11]. Since the publication of
that study, mast cells have been identified as a potential
source of MBP [10]. Taken together with our results, this
raises the possibility that both mast cells and eosinophils
represent sources of IL-11 in asthma. Transgenic mice that
overexpress IL-11 in the lung develop thickening of airway
walls, subepithelial fibrosis, and other local structural
changes [12]. Production of IL-11 thus may represent an
important link between IgE-dependent mast cell activa-
tion in subjects with allergic asthma and the development
of a spectrum of structural changes in the airways of these
individuals; such changes, that are collectively termed
"airway remodeling", constitute an increasingly recog-
nized long term consequence of asthma [2,12,13].BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/5
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Figure 1
Changes in gene expression in human mast cells stimulated via the Fcε RI (A) Clustering of 2,478 genes that exhib-
ited a 2–200 fold change in expression over baseline "0" levels in two human umbilical cord blood-derived mast cell populations
(> 99% purity) that were stimulated via the Fcε RI (with anti-IgE at 10 µg/ml) for 1 or 2 h. The microarrays were scanned on a
GenePix 4000 microarray scanner (Axon Instruments, Foster City, CA) and analyzed using Scan Alyze (M. Eisen;  [http://
rana.stanford.edu/software/] ) or GENEPIX PRO (Axon Instruments). Single spots or areas of the array with obvious blemishes
were flagged and excluded from subsequent analyses. All non-flagged array elements for which the fluorescent intensity in each
channel was greater than 1.4 times the local background were considered well measured. A set of clones that consistently
behaved poorly across arrays (time course) was identified and excluded from all analyses. The ratio values (experimental vs.
reference) were normalized according to the baseline (time 0) value of each donor (so that the level of baseline mRNA expres-
sion would appear black in our color scale) and log-transformed (base 2). Hierarchical clustering was applied using Cluster (M.
Eisen;  [http://rana.stanford.edu/software/] ). Genes were selected for this analysis if their expression level deviated from that
in the unstimulated (time 0) mast cells by at least a factor 2 in at least 1 time point. The values from two experiments from two
different donors (Donor 1 and 2) were analyzed simultaneously. The results were displayed with Tree View (M. Eisen;  [http://
rana.stanford.edu/software/] ). Changes in gene expression were depicted according to the color scale shown at the bottom.
The results are displayed in a table format, in which each row represents a series of measurements of mRNA levels for a single
gene, and each column represents the measured mRNA levels for all of the genes in a single sample of cells. Each cell is colored
to reflect expression of the corresponding gene in a specific cell sample, relative to its expression level prior to treatment with
anti-IgE. Green color represents decreased expression; red color represents increased expression. As indicated, the scale
extends from ratios of 0.125 to 8 (-3 to 3 in log base 2 units). Gray cells in the table indicate missing or excluded data. Genes
for (B) cytokines, (C) chemokines, (D) molecules that can regulate potential interactions with T cells, B cells, or dendritic cells,
and (E) adhesion molecules whose expression changed significantly (same populations as in (A)). * = Expression (or † = change
in expression after Fcε RI dependent stimulation) not previously reported for either human or rodent mast cells; ‡ = expres-
sion not previously reported for human mast cells.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/5
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Conclusions
Our initial analysis of the transcriptional program in-
duced in in vitro-derived human mast cells stimulated via
the Fcε RI has identified many products that heretofore
have not been associated with this cell type, but which
may significantly influence mast cell function in IgE-asso-
ciated host responses. We also have demonstrated that
mast cells stimulated via the Fcε RI can secrete IL-11, a cy-
tokine that may contribute to some of the tissue altera-
tions that occur in the airways of patients with asthma. In
future studies, it will be important to attempt to character-
ize the expression of IL-11 and the other potential prod-
ucts identified by our transcriptional analysis by specific
mast cell populations in vivo. It of course will also be im-
portant to examine the potential roles of the individual
mast cell-associated products identified in our cDNA
microarray analyses, including IL-11, in the inflamma-
tion, immune modulation and tissue remodeling associ-
ated with allergic disorders and immune responses to
parasites, as well as in the alterations of mast cell prolifer-
ation, survival and phenotype that can occur in these set-
tings. Finally, it will be of great interest to define the
programs of gene expression induced in mast cells by the
many other immunological and non-immunological fac-
tors that can mediate activation of this cell type independ-
ently of IgE. Such studies may provide additional insights
into the roles of this cell in health and disease.
Materials and methods
Umbilical Cord Blood-Derived Human Mast Cells
In vitro-derived human mast cells were obtained essential-
ly as described in Kempuraj et al.[14]; details of the culture
methods are available on the Stanford Microarray Data-
base web site ( [http://genome-www.stanford.edu/mast/]
). Cells from 11–19 wk cultures were used; mast cells rep-
resented > 99% of the total cells according to light micro-
scopic morphology in preparations stained with Kimura's
stain and 98% (1 population) or > 99% (all the others) of
the cells by immunohistochemistry for mast cell-associat-
ed tryptase [15]. In addition, these preparations consist of
cells that have high levels of c-kit expression by flow cy-
tometry (data not shown). Umbilical cord blood was ob-
tained under the guidelines of the Stanford University
Institutional Review Board.
Stimulation of Mast Cells via the Fcε RI
Mast cells were incubated for 4 days with purified human
myeloma IgE (5 µg/ml, Biodesign International, Kenneb-
unk, ME) and rhIL-4 (10 ng/ml, PeproTech, Rocky Hill,
NJ) to enhance surface expression of Fcε RI [15]. Dose re-
sponse studies indicated that substantial levels of hista-
mine release, reflecting a high level of Fcε RI-dependent
mast cell activation, could be achieved in these prepara-
tions by stimulating the mast cells with 10 or 1 µg/ml of
anti-human IgE antibody (Sigma); these concentrations
were used for all the experiments reported herein. Cells
were harvested immediately before or at 1 or 2 h after
stimulation with anti-IgE for microarray analyses. Hista-
mine release was assessed using the histamine enzyme im-
munoassay kit (Immunotech, Westbrook, ME) and IL-11
secreted into the medium was measured with a human IL-
11 immunoassay kit (R&D Systems, Minneapolis, MN).
Figure 2
Human mast cells stimulated via the Fcε RI secrete
IL-11 (A) Production of IL-11 by 3 different populations
(from Donors 4–6) of human umbilical cord blood-derived
mast cells (> 99% purity) that were incubated for 6 h without
anti-IgE ("0") or were maintained for 6 h after stimulation via
the Fcε RI with anti-IgE at 10 µg/ml. Data represent mean ±
s.e.m. for 2–3 determinations for each population. (B) Kinet-
ics of IL-11 production in human umbilical cord blood-
derived mast cells after stimulation via the Fcε RI with anti-IgE
at 1 µg/ml. Data represent mean ± s.e.m. for 3 different pop-
ulations of human mast cells (from Donors 7–9). Values for
anti-IgE stimulated vs. control cells were analyzed for statisti-
cal significance by the Student's t test, 2-tailed. Note: In ~20
experiments of this type, little or no IL-11 secretion was
detected in supernatants of mast cell preparations that were
sensitized with IgE and then incubated without anti-IgE for 6
h.
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cDNA Microarray Procedures
The cDNA microarray used in these experiments repre-
sents a set of ~14,000 genes related to immune function
[5]. All analyses were performed using poly(A) + mRNA
(extracted using the Fast Track kit, Invitrogen, Carlsbad,
CA) [17]. The experimental samples were our human
mast cell preparations; the control "reference" samples
represented a pool of mRNA isolated from a human mast
cell line (HMC-1, ref. 18), a T cell line (Jurkat), and a B cell
line (Raji). For each cell type, the mRNA used for the pool
consisted of that derived from unstimulated cells (80% of
the total) and stimulated cells (20% of the total); the con-
trol cell lines were stimulated with 1 µM Ionomycin (Sig-
ma) and 25 ng/ml phorbol 12-myristate 13-acetate (PMA;
Sigma) for 2 h at 37°C. The use of common control cDNA
probe allows the relative expression of each gene to be
compared across all samples.
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